Although STAT molecules are the ultimate effectors of JAK/STAT signaling, currently tested therapeutic applications in IBD predominantly target JAKs, thus interfering with the signaling of a variety of cytokines (Figure 3). The gene discussed is SOAT1; the disease is inflammatory bowel disease.